default author photo

Youngjin Lee

EuBiologics R&D Center

SCHOLARLY PAPERS

2

DOWNLOADS

213

TOTAL CITATIONS

0

Scholarly Papers (2)

1.

Safety, Immunogenicity and Lot-to-Lot Consistency of a Simplified, Whole Cell, Oral Cholera Vaccines (Euvichol-S) in Nepal: A Phase 3, Observer-Blinded, Randomized, Active-Controlled Trial

Number of pages: 24 Posted: 10 Jul 2023
International Vaccine Institute, Kanti Children’s Hospital, Kathmandu University Hospital - Dhulikhel Hospital, Kathmandu University Hospital - Dhulikhel Hospital, BP Koirala Institute of Health Sciences, Nepalgunj Medical College, International Vaccine Institute, International Vaccine Institute, International Vaccine Institute, International Vaccine Institute, International Vaccine Institute, International Vaccine Institute, International Vaccine Institute, International Vaccine Institute, International Vaccine Institute, International Vaccine Institute, International Vaccine Institute, International Vaccine Institute, International Vaccine Institute, Hilleman Laboratories Singapore Pte Ltd, EuBiologics R&D Center, EuBiologics R&D Center, EuBiologics R&D Center, EuBiologics R&D Center, EuBiologics R&D Center, EuBiologics R&D Center and International Vaccine Institute
Downloads 120 (596,393)

Abstract:

Loading...

Oral cholera vaccine, Safety, Immunogenicity, Euvichol-S, ShancholTM

2.

A Phase II/III, Multicenter, Observer-Blinded, Randomized, Non-Inferiority and Safety, Study of Typhoid Conjugate Vaccine (EuTCV) Compared to Typbar-TCV ® in Healthy 6 Months-45 Years Aged Participants

Number of pages: 27 Posted: 24 Oct 2022
EuBiologics R&D Center, EuBiologics R&D Center, EuBiologics R&D Center, EuBiologics R&D Center, EuBiologics R&D Center, EuBiologics R&D Center, EuBiologics R&D Center, EuBiologics R&D Center, EuBiologics R&D Center, EuBiologics R&D Center, Seoul National University, Seoul National University, Seoul National University and Seoul National University
Downloads 93 (725,554)

Abstract:

Loading...

Typhoid conjugate vaccine, immunogenicity, phase II/III clinical trial, safety